Coherus Oncology, Inc. (NASDAQ:CHRS) Given Consensus Recommendation of “Hold” by Analysts

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have received a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.0167.

Several equities analysts have issued reports on the company. Wall Street Zen upgraded Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer initiated coverage on Coherus Oncology in a research note on Thursday. They issued an “outperform” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Coherus Oncology in a research report on Wednesday, October 8th.

Coherus Oncology Stock Down 3.0%

Coherus Oncology stock traded down $0.05 during mid-day trading on Thursday, hitting $1.59. The company had a trading volume of 2,770,077 shares, compared to its average volume of 1,605,373. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42. Coherus Oncology has a 1 year low of $0.71 and a 1 year high of $1.89. The business has a fifty day moving average of $1.37 and a 200 day moving average of $1.32. The stock has a market cap of $192.18 million, a price-to-earnings ratio of 1.20 and a beta of 0.96.

Coherus Oncology (NASDAQ:CHRS) last posted its earnings results on Thursday, November 6th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $11.57 million during the quarter, compared to analysts’ expectations of $13.41 million. On average, sell-side analysts expect that Coherus Oncology will post -1.05 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Coherus Oncology

Several hedge funds have recently added to or reduced their stakes in CHRS. Strs Ohio acquired a new position in Coherus Oncology in the 1st quarter valued at $261,000. Panagora Asset Management Inc. acquired a new position in Coherus Oncology in the second quarter valued at $581,000. International Assets Investment Management LLC purchased a new position in Coherus Oncology during the second quarter worth about $33,000. Corient Private Wealth LLC boosted its stake in Coherus Oncology by 20.0% in the 2nd quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock worth $44,000 after buying an additional 10,000 shares during the last quarter. Finally, Voya Investment Management LLC acquired a new stake in Coherus Oncology in the 3rd quarter worth about $28,000. 72.82% of the stock is currently owned by hedge funds and other institutional investors.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.